Number of targeted therapeutics awaiting FDA approval on the rise
The success of these types of drugs has been noted by pharmaceutical firms who are adding them to their development portfolios.
By Susan J. Landers, AMNews staff. Posted Feb. 9, 2009.
Several innovative therapies targeted at the cellular level to treat complex diseases such as cancer are beginning to fill the drug development pipeline.
But they also are likely to remain in the pipeline for a while, given the need for a longer clinical development process dictated by the Food and Drug Administration and by the complexity of the diseases they are intended to treat, according to "Outlook 2009," a report released Jan. 6 by the Tufts Center for the Study of Drug Development at Tufts University in Boston./.../
No comments:
Post a Comment